Agenus Inc. · NASDAQ:AGEN
Agenus — Jefferies 2018 Healthcare Conference
22 slides from Agenus's conference presentation, Jun 7, 2018
Slide 1: Jefferies 2018 Healthcare Conference
Jefferies 2018 Healthcare Conference June 7, 2018
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q fil
Slide 3: Who is Agenus?
Process Who is Agenus? chart with three phases 1994 2000 2014 to Present Therapeutic cancer Acquired QS-21 Built an innovation vaccines World’s best adjuvant engine Team to execute GMP Personalized Individualized Medicine Medicine Manufacturing Acquired/Built End to End capabilities Discovery – cell
Slide 4: Process today: innovation and speed
chart – Process today Agenus with innovation three phases and speed I-O Capabilities Speed & Optimal & Portfolio Efficiency Combinations 4 Therapeutic modalities CPMs, Vaccines, Cell 5 INDs^ Filed in 2016 – 2017 I-O backbone CTLA-4 and PD-1 Therapy*, Adjuvants INDs^ Technology platforms 6 On track f
Slide 5: Key acquisitions
Key acquisitions Discovery and development of checkpoint antibodies QS-21 Stimulon® • >12 programs • Most powerful adjuvant • Cell line development • Adjuvant in most effective Shingles • GMP manufacturing vaccine (SHINGRIX) Integrated GMP Antibody Manufacturing • Rapid discovery to clinical materia
Slide 6: Agenus portfolio designed for rapid BLA & market expansion
Agenus portfolio designed for rapid BLA & market expansion Product Disease/Target Partner Preclinical Ph1 Ph2 Ph3 Filed Approved Checkpoint Antibodies AGEN1884 CTLA-4 (antagonist) AGEN1181 Next-Gen CTLA-4 (antagonist) Agenus fully-owned programs AGEN2034 PD-1 (antagonist) Partnered programs AGEN1423
Slide 7: Agenus therapies enable effective combinations
Agenus therapies enable effective combinations Foundational PD-1 & CTLA-4 Checkpoint Modulators (CPMs) Enable Combination Checkpoint Phase II 2L Cervical Cancer Ongoing – BLA 2020 Therapy with Blockade Additional Studies Planned Validated Targets First-in-Class TME Conditioning Agents – 2 INDs 2018
Slide 8: Delivering on our partnerships
Delivering on our partnerships Shingrix with Agenus Multiple combination 1 undisclosed target QS-21 Stimulon® Ph2s ongoing: • Lead selection completed • Most effective Shingles • INCAGN1876 (GITR) vaccines (up to 97% • INCAGN1949 (OX-40) • Initial milestone received; efficacy) • Dose escalation comp
Slide 9: Foundational Checkpoint Antibodies
Foundational Checkpoint Antibodies Critical enablers of I-O combination therapy
Slide 10: PD-1 and CTLA-4 are backbone innovative combinations
PD-1 and CTLA-4 are backbone innovative combinations PD-1 / CTLA-4 is validated I-O/I-O antibody combination NEXT-GENERATION CTLA-4 +/- PD1 Therapies (cell therapy, mAbs, AGEN20341: VALIDATED Targets bispecifics, ADCs, Anti-PD-1 mAb – targeted therapies, Phase 2 ongoing vaccines, etc.) AGEN18841: Po
Slide 11: AGEN1884 (CTLA-4) and AGEN2034 (PD-1) – Clinically Active
AGEN1884 (CTLA-4) and AGEN2034 (PD-1) – Clinically Active • >100 patients treated; clinical benefit in 30 – 40% of patients with advanced refractory cancer • Combination in 2L Cervical Cancer advancing Complete responder post CTLA-4 (AGEN1884) Dose Frequency AGEN1884 treatment AGEN1884 0.1, 0.3, 1,
Slide 12: Planned Path to BLA: AGEN2034 (PD-1) & AGEN1884 (CTLA-4)
Planned Path to BLA: AGEN2034 (PD-1) & AGEN1884 (CTLA-4) 2017 2018 2019 2020 Q1 Q2 Q3 Q4 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 AGEN1884 Ph 1 AGEN2034 P1/2 Trials designed as registrational trials to support a rapid BLA filing AGEN1884 plus AGEN2034 2L Cervical cancer* AGEN1884 and AGEN2034 undis
Slide 13: Expanding Beyond CTLA-4 & PD-1
Expanding Beyond CTLA-4 & PD-1 Enabling cancer immune modulation beyond the T cell
Slide 14: High Throughput Discoveries; New Clinical Programs in ~2yrs
High Throughput Discoveries; 6 New Clinical Programs in ~2yrs* HIT HIT LEAD CELL LINE ASSET DISCOVERY OPTIMIZATION OPTIMIZATION DEVELOPMENT Undisclosed bispecific #1 First-in-class Opportunity Treg depletion, agonist costimulation Undisclosed bispecific #2 First-in-class Opportunity TME conditioning
Slide 15: Next-Generation CTLA-4 with Novel Mechanisms – Planned IND 2018
Next-Generation CTLA-4 with Novel Mechanisms – Planned IND 2018 Mechanism #1 Mechanism #2 Mechanism #3 Blockade of CD80 & CD86 Depletion of intratumoral Tregs Agenus discovery binding to CTLA-4 via co-engagement of FcγRs Enhanced T cell priming Primary T cell Assay 15000 Ligand blocking assay IL -2
Slide 16: Best in Class & First in Class Bispecifics – Planned for IND in 2018
Best in Class & First in Class Bispecifics – Planned for IND in 2018 • Regulatory T cells impair productive anti-tumor immune responses with multiple mechanisms of suppression • Targeted elimination of regulatory T cells within the TME would address multiple suppressive mechanisms (i.e. in a single
Slide 17: Neoantigen Vaccine Platform
Neoantigen Vaccine Platform Enabling differentiated personalized and warehouse vaccine offerings
Slide 18: ASV Clinically Validated Neoantigen Vaccine Platform
ASV™ Clinically Validated* Neoantigen Vaccine Platform ASVTM Clinical Status • Clinical safety & immunogenicity with ASVTM • Potential best-in-class vaccine blueprint neoantigen vaccine platform demonstrated* with QS-21 Stimulon® adjuvant for efficacy • Combo with CPMs planned for 2018 and manufactu
Slide 19: www.agentustherapeutics.com www.agenusbio.com
www.agentustherapeutics.com www.agenusbio.com
Slide 20: Bruno Lucidi, CEO AgenTus
Bruno Lucidi, CEO AgenTus • 30 years of industry experience • Vice President and Head of Pediatric Vaccines at GSK Vaccines (developed $3bn global business) • Worldwide Vice-President Virology & Oncology at Johnson & Johnson • Leadership at Bristol-Myers Squibb responsible for EU strategy and launch
Slide 21: Differentiated Cancer Cell Therapy
Differentiated Cancer Cell Therapy Precision T-Rx Mammalian Display - Direct selection for function Receptors Targets optimal balance between activity and specificity Novel Proprietary target discovery and validation platforms Targets Proprietary Phosphopeptide Tumor Targets Allogeneic Allogeneic ap
Slide 22: www.agentustherapeutics.com www.agenusbio.com www.agentustherapeutics.com
www.agentustherapeutics.com www.agenusbio.com www.agentustherapeutics.com